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Background: Many cancer research studies have extensively examined the phosphatase and tensin homolog
deleted from chromosome 10 (PTEN) pathway. There are only few reports that suggest that PTEN might affect pain;
however, there is still a lack of evidence to show the role of PTEN for modulating pain. Here, we report a role for
PTEN in a rodent model of neuropathic pain.
Results: We found that chronic constriction injury (CCI) surgery in rats could elicit downregulation of spinal PTEN
as well as upregulation of phosphorylated PTEN (phospho-PTEN) and phosphorylated mammalian target of
rapamycin (phospho-mTOR). After examining such changes in endogenous PTEN in neuropathic rats, we explored
the effects of modulating the spinal PTEN pathway on nociceptive behaviors. The normal rats exhibited mechanical
allodynia after intrathecal (i.t.) injection of adenovirus-mediated PTEN antisense oligonucleotide (Ad-antisense PTEN).
These data indicate the importance of downregulation of spinal PTEN for nociception. Moreover, upregulation of
spinal PTEN by i.t. adenovirus-mediated PTEN (Ad-PTEN) significantly prevented CCI-induced development of
nociceptive sensitization, thermal hyperalgesia, mechanical allodynia, cold allodynia, and weight-bearing deficits in
neuropathic rats. Furthermore, upregulation of spinal PTEN by i.t. Ad-PTEN significantly attenuated CCI-induced
microglia and astrocyte activation, upregulation of tumor necrosis factor-α (TNF-α) and phospho-mTOR, and
downregulation of PTEN in neuropathic rats 14 days post injury.
Conclusions: These findings demonstrate that PTEN plays a key, beneficial role in a rodent model of neuropathic pain.
Keywords: Chronic constriction injury, Intrathecal, Astrocyte, NeuroinflammationBackground
Pain affects 1.5 billion people globally, including 116
million people in the USA and 164 million people in
Europe and Israel combined [1]. The 2009 global pain
market was estimated to be over US $50 billion [2]. Pre-
vious studies indicated that chronic pain occurs in about
20% of the general population [3,4], and the prevalence
of neuropathic pain is 6.9% [4]. In a review of 174 trials* Correspondence: minghongtai@gmail.com; wzh@mail.nsysu.edu.tw
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unless otherwise stated.published, Finnerup et al. [5] reported that there are no
drug treatments available that can relieve all neuropathic
pain conditions. Moreover, the detailed mechanisms
underlying neuropathic pain still remain unclear.
The phosphatase and tensin homolog deleted from
chromosome 10 (PTEN) is a tumor suppressor of phos-
phatased activity [6]. PTEN has been studied extensively
through cancer research [7,8]; however, there are only
few reports that suggest that PTEN might affect pain
[9]. Goebbels et al. have demonstrated that by targeted
disruption of Pten in Schwann cells that causes focal
hypermyelination in the PNS and is associated with pro-
gressive peripheral neuropathy in mice [9]. However,
there is still a lack of evidence to show the role of PTENThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inhibitory mediator of mammalian target of rapamycin
(mTOR) [10-12]. Several studies have demonstrated that
inhibition of the spinal mTOR pathway can attenuate
nociception in neuropathic pain [13,14]. We suspect that
PTEN upregulation may have a therapeutic effect on
neuropathic pain.
Here, we use a rat model of chronic constriction injury
(CCI)-induced neuropathic pain combined with an intra-
thecal (i.t.) delivery system to determine whether central
PTEN plays a role in neuropathic pain. We examined
changes in endogenous spinal PTEN in neuropathic rats
using our adenovirus-mediated target gene overexpres-
sion system. This system has been shown to be stable
and effective in rodent models, especially adenovirus-
mediated PTEN (Ad-PTEN) in in vitro mouse models
[15] and in both ex vivo [16] and in vivo [17] rat models.
Additionally, we examined whether modulating the
spinal PTEN pathway affected nociceptive behaviors
that were measured reliably with behavioral pain assays
[18,19]. Spinal neuroinflammation may accelerate central
sensitization and promote the development and mainten-
ance of neuropathic pain [20,21]. Furthermore, spinal neu-
roinflammation in CCI is characterized by microglial and
astrocytic activation and increased expression of the pro-
inflammatory mediator tumor necrosis factor-α (TNF-α)
[19,22]. Many studies have further demonstrated that inhi-
biting microglial and astrocytic activation can have anal-
gesic effects [19,23-25]. Similarly, TNF-α reportedly plays
key roles in neuropathic pain [26,27], whereas, inhibition
of spinal TNF-α inhibits neuropathic pain behavior [28].
In the present study, we examine whether PTEN affects
spinal microglial and astrocytic activation and upregula-
tion of TNF-α accompanied the nociceptive behaviors in
CCI rats. In addition, we examine whether PTEN affects




We housed the male Wistar rats (260 to 285 g) for free
access to food and water in a temperature-controlled
(22°C ± 1°C) and light-cycle-controlled (12-h light/12-h
dark) room. After the approval by the National Sun Yat-
sen University and Use Committee, we conformed to
the Guiding Principles in the Care and Use of Animals
of the American Physiology Society to use rats through-
out the experiments. For surgery and drug injections, all
rats were anesthetized under isoflurane inhalation (2%).
Then, for preventing infection during the surgery, all
rats received intramuscularly postoperative injection of
veterin (cefazolin; 0.17 g/kg). Our every effort in experi-
mental design and execution was on the purpose of min-
imizing the suffering and number of rats we used.Induction of peripheral mononeuropathy (CCI)
As described by Bennett and Xie [29] and our previous
studies [19,23], we performed the surgery of CCI to the
right sciatic nerve of rats, to expose the right sciatic
nerve of rats (at mid-thigh level), to dissect a 5-mm-long
nerve segment of the sciatic nerve, to place four loose
ligatures (4 to 0 chromic gut) around the sciatic nerve
(with 1-mm intervals), and then to suture muscle and
skin incision layer by layer. For the sham-operated rats,
the surgery was performed only to expose the right sci-
atic nerve but without ligation.
Implantation of i.t. catheters
Using the method described in Yaksh and Rudy [30] and
our previous studies [19,23], we inserted i.t. catheter
(PE5 tubes: 9-cm long, 0.008-in. inner diameter, 0.014-
in. outer diameter; Spectranetics, Colorado Springs, CO,
USA) to the lumbar enlargement of the spinal cord via
the atlanto-occipital membrane at the base of the rat’s
skull down, and then externalized and fixed one end of
the i.t. catheter to the cranial aspect of the rat’s head for
spinal drug administration. Because the dead volume of
i.t. catheter was 3.5 μL, to ensure complete drug deliv-
ery, an i.t. artificial cerebrospinal fluid (aCSF) flush
(10 μL) followed all i.t. injections. The composition of
aCSF is as follows: 151.1 mM Na+, 2.6 mM K+, 1.3 mM
Ca2+ , 0.9 mM Mg2+, 122.7 mM Cl−, 21.0 mM HCO3
−,
2.5 mM HPO4
2−, and 3.5 mM dextrose and bubbled with
5% CO2 in 95% O2 for adjusting the final pH to 7.3. Five
days after implantation of i.t. catheters, we excluded rats
with i.t. catheter that had the fresh blood in the CSF or
exhibit of gross neurological injury from the following
experiments. According to the method described in
other previous study [31] and our previous studies
[19,23], we evaluated the locomotor function of rats
using the Basso, Beattie, and Bresnahan (BBB) locomotor
scale [32].
Preparation of adenovirus vectors
Using the method described in our previous reports
[15-17], we prepared E1- and E3-defective recombinant
adenovirus vectors encoding green fluorescent protein
(Ad-GFP), PTEN antisense oligonucleotide (Ad-antisense
PTEN), or human PTEN cDNA (Ad-PTEN). These adeno-
virus solutions were tittered with a plaque-forming assay,
aliquoted, and then stored at −80°C before their use.
Nociceptive behavioral testing
(i.) Thermal hyperalgesia test: After we placed each rat
into each compartment of clear plastic cages onto an ele-
vated glass platform, we then used an IITC analgesiometer
(IITC Inc., Woodland Hills, CA, USA) to test thermal
hyperalgesia as described previously by Hargreaves et al.
[33] and our previous study [18,34] to position a radiant
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onto the middle of the plantar surface of the rat, with a
cutoff time of 30 s, to measure the paw withdrawal latency
(PWL; in seconds) of the rat until the rat showed a posi-
tive sign of pain behavior (licking or withdrawal).
(ii.) Mechanical allodynia test: After we set each rat
into each compartment of clear plastic cages onto an el-
evated metal mesh floor for easy access to the rats’ paws,
we measured hindpaw withdrawal threshold (PWT; in g)
to assess mechanical allodynia using calibrated von Frey
filaments (Stoelting, Wood Dale, IL, USA). Then, we
apply a series of von Frey filaments of logarithmically in-
cremental stiffness to the midplantar region of the rat
hindpaw by Chaplan’s ‘up-down’ method to determine
the closest filament to the threshold of pain response
(licking or withdrawal) of the rat as described previously
by Chaplan et al. [35] and our previous studies [18,19].
(iii.) Cold allodynia test: As described previously by our
previous study [18], after we placed each rat in the individ-
ual plastic compartments on an elevated metal mesh floor,
cold allodynia response (acetone response score; in point)
of the rat was monitored during 1 min following acetone
stimulus (25 μl) onto the center of the plantar surface of
rats’ hindpaw. Modified from 4-point scale of previous
studies [36,37], acetone response scores of the paw were
graded according to a 6-point scale: 0, repeated flicking
with persistent licking in 2 s following acetone stimulus; 1,
prolonged withdrawal or repeated flicking in 2 s following
acetone stimulus; 2, quick and more violent withdrawal,
flick, or stamp in 2 s following acetone stimulus; 3, quick
withdrawal, flick, or stamp in 2 s following acetone stimu-
lus; 4, withdrawal, flick, or stamp more than 2 s following
acetone stimulus; and 5, no response. Then, to sum the four
individual scores for obtaining acetone response score of
the paw of each rat. The minimum possible total score of
the paw could be 0 point (the rat exhibits repeated flicking
and licking of paws on each of the four trials), and the max-
imum possible total score of the paw could be 20 points
(the rat exhibits no response to any of the four trials).
(iv.) Weight-bearing test: To let the rat place its hind-
paws onto the two force transducers of the incapacitance
tester (Singa Technology Corporation, Taoyuan, Taiwan,
Republic of China) for measuring the hindpaw weight-
bearing deficits (change in hindpaw weight distribution; in
g) as described in our previous study [18,38]. Under nor-
mal conditions, the naïve rat distributes weight equally
between both hind limbs, but after inducing inflammation
of one hind limb (like CCI), the rat redistributes weight
for lowering weight-bearing of the affected limb [39].
Change in hindpaw weight distribution of the rat was
expressed as a difference by subtracting the affected limb
(the right hind limb; the ipsilateral side) from the normal
limb (the left hind limb; the contralateral side) measured
at the same time.Spinal immunohistofluorescence analysis
For reducing variations in immunohistochemical proce-
dures, we mounted the lumbar spinal tissues from the dif-
ferent groups of rats into the same OCT block, sectioned
these spinal tissues together using a cryostat at −30°C
(HM550; Microm, Waldorf, Germany) and performed the
following spinal immunohistofluorescence analysis, with a
modified method described in Sung et al. [40] and our
previous studies [18,23]. The spinal sections (10 μm) were
incubated with primary antibody, anti-phosphorylated
PTEN (anti-phospho-PTEN; Ser380) (1:200 dilution, cat.
9551; Cell Signaling Technology Inc., Beverly, MA, USA;
polyclonal rabbit antibody), anti-PTEN (1:200 dilution,
cat. 10005059; Cayman Chemical, Ann Arbor, MI, USA;
polyclonal rabbit antibody), anti-phosphorylated mTOR
(anti-phospho-mTOR; Ser2448) (1:200 dilution, cat. 2976;
Cell Signaling Technology Inc., Beverly, MA, USA; poly-
clonal rabbit antibody), anti-OX-42 (CD11b, microglial
marker, 1:200 dilution, cat. CBL1512; EMD Millipore, Te-
mecula, CA, USA; monoclonal mouse antibody), anti-glial
fibrillary acidic protein (GFAP) (astrocytic marker, 1:200
dilution, cat. MAB3402; EMD Millipore, Temecula, CA,
USA; monoclonal mouse antibody), or anti-TNF-α (1:200
dilution, cat. ARC3012; Life Technologies Corporation,
Grand Island, NY, USA) overnight at 4°C. This was then
followed by Alexa Fluor 488-labeled chicken anti-mouse
IgG antibody (1:400 dilution, cat. A-21200; Molecular
Probes, Eugene, OR, USA; green fluorescence) or DyLight
549-conjugated donkey anti-rabbit IgG antibody (1:400 di-
lution, cat. 711-506-152; Jackson ImmunoResearch La-
boratories Inc., West Grove, PA, USA; red fluorescence)
for 40 min at room temperature. For immunostaining
analysis, we use a Leica DM-6000 CS fluorescence micro-
scope (Leica Instruments Inc., Wetzlar, Germany) for
examination of these stained spinal sections, and then use
a SPOT Xplorer Digital camera (Diagnostic Instruments,
Inc., Sterling Heights, MI, USA) for photographing all im-
munofluorescence images of phospho-PTEN, PTEN,
phospho-mTOR, OX-42, GFAP, and TNF-α, respectively.
We measured the pixel values of the immunoreactive-
positive area (using three sections per rat) by Image J
software (National Institutes of Health, Bethesda, MD,
USA). Spinal neurons located in the superficial laminae,
laminae I to III, respond to nociceptive stimuli and directly
participate in the transmission of nociception to the brain
[41], and thereby the superficial laminae play a more import-
ant role in neuropathic pain than the deep laminae. There-
fore, in accordance to the method used for neuropathic
rodents [41-44], we focused on quantifying the immuno-
reactivity of the targeted protein in the superficial laminae
of the spinal cord. The immunofluorescence data were
expressed as a percentage change compared to sham-
operated or sham-operated plus i.t. vehicle group, which
were considered to be 100%. For double-immunofluorescent
Huang et al. Journal of Neuroinflammation  (2015) 12:59 Page 4 of 18staining of PTEN and neuronal marker, the spinal sections
were incubated with a mixture of anti-PTEN (1:200 dilu-
tion) and anti-Neuronal Nuclei (NeuN) (neuronal-specific
nuclear protein; neuronal marker, 1:500, Alexa Fluor 488
conjugated antibody, cat. MAB377X, EMD Millipore,
Temecula, CA, USA; monoclonal mouse antibody) anti-
bodies overnight at 4°C, and then followed by DyLight
549-conjugated anti-rabbit IgG antibody (1:400 dilution)
for 40 min at room temperature. On the other hand, for
double-immunofluorescent staining of PTEN and micro-
glial marker or astrocytic marker, the spinal sections were
incubated with a mixture of anti-PTEN (1:200 dilution)
and OX-42 (1:200 dilution) or GFAP (1:200 dilution) anti-
bodies overnight at 4°C, and then followed by a mixture of
Alexa Fluor 488-conjugated anti-mouse IgG antibody
(1:400 dilution) and DyLight 549-conjugated anti-rabbit
IgG antibody (1:400 dilution) for 40 min at room temperature.
For double-immunofluorescent staining of anti-TNF-α or
phospho-mTOR and astrocytic marker, the spinal sections
were incubated with a mixture of anti-TNF-α (1:200 dilu-
tion) or anti-phospho-mTOR (1:200 dilution) and GFAP
(1:200 dilution) antibodies overnight at 4°C, and then
followed by a mixture of DyLight 549-conjugated anti-
rabbit IgG antibody (1:400 dilution) and Alexa Fluor 633-
conjugated goat anti-mouse IgG antibody (1:400 dilution,
cat. A21052; Life Technologies Corporation) for 40 min at
room temperature. The double-immunostaining images
were examined and acquired with Leica TCS SP5 II
confocal microscope (Leica Instruments Inc., Wetzlar,
Germany). We set the color of TNF-α or phospho-mTOR
for 549-nm excitation line as pseudo red and set the color
of GFAP for 633 nm excitation line as pseudo green.
When co-localization of two proteins occurred, the merge
of above two colors, pseudo red (TNF-α or phospho-
mTOR) and pseudo green (GFAP), yielded yellow color.
Western blot analysis
Following our published method [22,34,45], we per-
formed Western blotting analysis on the ipsilateral side
of the lumbar spinal dorsal samples from the rats. For
Western blotting analysis, we collected and washed
spinal dorsal samples from rats with ice-cold PBS, and
then used a Polytron homogenizer (5 cycles of 10 s at
3,000 rpm) to homogenize in ice-cold lysis buffer (1 μg/ml
aprotinin, 50 mM Tris, 150 mM NaCl, 100 μg/ml phenyl-
methylsulfonyl fluoride, 1% Triton X-100, pH 7.5). After
centrifuging at 20,000 × g for 60 min at 4°C, we retained
this supernatant for Western blot analysis of phospho-
PTEN and PTEN. Modified from the method of Lowry
et al. [46], we determined the protein concentrations of
the supernatant with the DC protein assay kit (Bio-Rad,
Hercules, CA, USA). We added an equal volume of
sample buffer (2% 2-mercaptoethanol, 10% glycerol, 0.1%
bromophenol blue, 50 mM Tris–HCl, pH 7.2, and 2%sodium dodecyl sulfate (SDS)) to the supernatant. Then,
we electrophoresed the proteins of supernatant through a
tricine SDS-polyacrylamide gel at 150 V for 90 min and
transferred the proteins within the gel to a polyvinylidene
difluoride membrane (PVDF membrane; Immobilon-P,
Millipore, 0.45-μM pore size) in transfer buffer (380 mM
glycine, 1% SDS, 50 mM Tris–HCl, 20% methanol) at
125 mA overnight at 4°C. With blocking PVDF membrane
for 1 h at room temperature using 5% non-fat dry milk in
Tris-buffered saline (TTBS; 137 mM NaCl, 0.1% Tween
20, 20 mM Tris–HCl, pH 7.4), we then incubated the
PVDF membrane with antibodies against phospho-PTEN
(Ser380; 1:1,000 dilution) or PTEN (1:1,000 dilution) pro-
teins for 180 min at room temperature. The antibodies
recognized immunoreactive bands of phospho-PTEN (ap-
proximately 54 kDa) and PTEN (approximately 47 kDa)
protein, which were visualized with enhanced chemilu-
minescence (ECL kit; Millipore) and photographed using
the UVP BioChemi imaging system (UVP LLC, Upland,
CA, USA), respectively. Finally, we performed the relative
densitometric quantification of the immunoreactive bands
of phospho-PTEN and PTEN protein with LabWorks 4.0
software (UVP LLC, Upland, CA, USA), and relative varia-
tions between the bands of the sham-operated or sham-
operated plus i.t. vehicle group and the other groups were
calculated using the same image. In addition, we reprobed
the PVDF membranes using an anti-β-actin antibody
(1:2,500 dilution; catalog no. A5441; Sigma Co., Ltd., St
Louis, MO, USA; monoclonal mouse antibody), which
was the loading control.
Data and statistical analysis
We showed all following data as means ± standard error
on the mean (SEM). For statistical analysis, we calculated
differences between groups of rats by a one-way analysis
of variance (ANOVA), used the Student-Newman-Keuls
post hoc test, and then defined the criterion for statistical
significance as P < 0.05.
Results
The time course of changes of endogenous spinal PTEN
in neuropathic rats
To explore any potential changes in the spinal PTEN
pathway in neuropathic rats, we prepared the lumbar
spinal tissues from the following eight groups of rats: (1)
1 day after sham operation, (2) 3 days after sham oper-
ation, (3) 7 days after sham operation, (4) 14 days after
sham operation, (5) 1 day after CCI, (6) 3 days after CCI,
(7) 7 days after CCI, and (8) 14 days after CCI. We per-
formed a spinal immunohistofluorescence analysis using
three antibodies against phospho-PTEN, PTEN, and
phospho-mTOR to evaluate the expression of the PTEN
pathway in the ipsilateral side of the lumbar spinal dor-
sal gray matter in neuropathic rats. Compared with the
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increased for phospho-PTEN but decreased for PTEN, 7
(Figure 1B,E) and 14 days (Figure 1C,F) after CCI. Similar
to the findings in a previous study [47], phospho-mTOR
immunoreactivity increased 7 (Figure 1H) and 14 days
(Figure 1I) after CCI, as compared with that of the sham-
operated group (Figure 1G). Quantification of the immu-
noreactivity results further confirmed phospho-PTEN
(Figure 1J) and phospho-mTOR (Figure 1L) upregulation,
as well as PTEN downregulation (Figure 1K), 3, 7, and
14 days after CCI. Further, we used Western blot analysis
to verify changes in endogenous PTEN in the dorsal horn
of the lumbar spinal cord (Figure 2A). The Western
blot analysis revealed upregulation of phospho-PTEN
(Figure 2B) and downregulation of PTEN (Figure 2C)
14 days after CCI surgery. To examine the cellular specifi-
city of endogenous PTEN in the dorsal horn of the lumbarFigure 1 The time course effects of CCI on spinal phospho-PTEN, PTE
sham-operated (A, D, G), 7 days after CCI (B, E, H), and 14 days after CCI (
phospho-PTEN (red, (A-C)), PTEN (green, (D-F)), and phospho-mTOR (red, (
(K), and phospho-mTOR (L) immunoreactivity in the ipsilateral dorsal horn
compared with sham-operated rats. Each bar in panels (J-L) represents the
immunoreactivity of phospho-PTEN and phospho-mTOR and downregulate
p-mTOR, phosphorylated mammalian target of rapamycin; PTEN, phosphat
phosphorylated PTEN. Scale bars: 200 μm for all images (A-I). *P < 0.05 comspinal cord, we prepared lumbar spinal tissues from the
sham-operated group for double-immunofluorescent
staining. Confocal double-immunostaining images of the
lumbar spinal dorsal gray matter of sham-operated rats
further confirmed that most PTEN signals were more
often co-localized with GFAP-positive cells (astrocytes,
Figure 2E) than NeuN-positive (neuronal cells; Figure 2D)
or OX-42-positive cells (microglial cells, Figure 2F).
The effect of i.t. Ad-antisense PTEN on nociceptive responses
To explore the effects of modulating spinal PTEN path-
way on nociceptive behaviors in normal rats, we pre-
pared the following five groups of rats: (1) naïve, (2) i.t.
vehicle, (3) i.t. Ad-GFP, (4) i.t. Ad-antisense PTEN, and
(5) i.t. Ad-PTEN. Five days after implantation of the i.t.
catheters, the rats received i.t. injection of vehicle, Ad-
GFP, Ad-antisense PTEN, or Ad-PTEN. No significantN, and phospho-mTOR. Spinal cord sections (10 μm) were from the
C, F, I) groups. Immunostaining images show cells labeled with
G-I)) in the spinal cord. Quantification of phospho-PTEN (J), PTEN
of the lumbar spinal gray matter 1, 3, 7, and 14 days after CCI as
mean ± SEM; six rats per group. CCI significantly upregulated spinal
d spinal PTEN immunoreactivity. CCI, chronic constriction injury;
ase and tensin homolog deleted from chromosome 10; p-PTEN,
pared with the sham-operated group.
Figure 2 Changes in cellular specificity of endogenous PTEN in the dorsal horn of the spinal cord. (A) Western blots for phospho-PTEN,
PTEN, and β-actin proteins from sham-operated and 14 days after CCI groups; (B) relative density of immunoblot of phospho-PTEN; (C) relative
density of immunoblot of PTEN. Relative band intensities of phospho-PTEN and PTEN were quantified by densitometry and indicated as the
percent change relative to that for the sham-operated group (100%). Western blotting of spinal dorsal horn tissue homogenate revealed
that phospho-PTEN and PTEN protein expression was detectable in the sham-operated group, but CCI evoked upregulation of phospho-PTEN
protein and downregulation of PTEN protein 14 days after CCI. Western blotting of β-actin was performed to verify the equivalent amounts of
protein were loaded in each lane. Confocal double-immunofluorescent staining of PTEN (red) with NeuN (neuronal-specific marker; (D), green),
GFAP (astrocyte specific marker; (E), green) OX-42 (microglial specific marker; (F), green) in the dorsal horn region of the lumbar spinal cord of
sham-operated group. The merged images of (D), (E), and (F) (yellow; white arrow) indicate co-localization of PTEN with NeuN, GFAP, and
OX-42 immunoreactive cells in the spinal cord, respectively. The confocal results showed that spinal PTEN was primarily co-localized with
astrocytes. Scale bars are 50 μm for all images (D-F). Each bar in (B) and (C) represents the mean ± SEM with three rats per group. CCI-14 day:
14 days after CCI. *P < 0.05 compared with sham-operated group. CCI, chronic constriction injury; PTEN, phosphatase and tensin homolog
deleted from chromosome 10; p-PTEN, phosphorylated PTEN.
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not shown) and the i.t. vehicle group for PWL, PWT,
or acetone response scores. Compared with i.t. vehicle
group, i.t. Ad-GFP did not significantly affect PWL
(Figure 3A), PWT (Figure 3B), and acetone response
score (Figure 3C) of rats. After i.t. injection of Ad-
antisense PTEN, the rats exhibited mechanical allodynia
(Figure 3B) but not thermal hyperalgesia (Figure 3A)
and cold allodynia (Figure 3C) from 3 to 7 days com-
pared with that of i.t. Ad-GFP group. Compared with i.t.
Ad-GFP group, i.t. Ad-PTEN did not significantly affect
PWL (Figure 3A), PWT (Figure 3B), and acetone re-
sponse score (Figure 3C) of rats. In addition, in the
present study, i.t. Ad-GFP, Ad-antisense PTEN, or Ad-PTEN-treated rats did not exhibit any obvious abnormal
external behavior (including locomotor function).
The inhibitory effects of Ad-PTEN on nociception in
neuropathic rats
To verify that Ad-PTEN has the ability to upregulate
production of spinal PTEN, we prepared the following
three groups of rats: (1) naïve plus i.t. vehicle, (2) naïve
plus i.t. Ad-GFP, and (3) naïve plus i.t. Ad-PTEN. We
observed no significant difference in spinal PTEN ex-
pression between naïve rats plus i.t. vehicle (Figure 4A)
and rats examined 14 days after i.t. injection of Ad-GFP
(Figure 4B), whereas PTEN immunoreactivity increased
14 days after i.t. Ad-PTEN (Figure 4C). Quantification of
Figure 3 Time course of the effects of i.t. Ad-antisense PTEN on nociceptive behaviors in normal rats. The naïve rats exhibited mechanical
allodynia (B) but not thermal hyperalgesia (A) and cold allodynia (C) from 3 to 7 days after i.t. injection of Ad-antisense PTEN. These data indicate
the importance of downregulation of spinal PTEN for nociception. Each point represents the mean ± SEM with six rats per group. *P < 0.05
compared with vehicle group. Ad-GFP, adenovirus-mediated green fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin
homolog deleted from chromosome 10; Ad-antisense PTEN, adenovirus-mediated PTEN antisense oligonucleotide.
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firmed that PTEN upregulation in the naïve plus i.t.
Ad-PTEN group 14 days after i.t. injection. Confocal
double-immunostaining images of the lumbar spinal
dorsal gray matter further confirmed most PTEN signals
were more often co-localized with GFAP-positive cells
(astrocytes; Figure 4F) than NeuN-positive (neuronal
cells; Figure 4E) or OX-42-positive cells (microglial cells;
Figure 4G) in the naïve rats administered i.t. Ad-PTEN.
To examine whether spinal PTEN upregulation in-
duced with i.t. Ad-PTEN affected neuropathic pain be-
haviors, we prepared the following three groups of rats:
(1) CCI plus i.t. vehicle, (2) CCI plus i.t. Ad-GFP, and (3)
CCI plus i.t. Ad-PTEN. Five days after the i.t. catheters
were implanted, the rats underwent CCI surgery, and
the vehicle, Ad-GFP, or Ad-PTEN was administered i.t.
immediately afterwards. Similar to previous findings
[48], CCI promoted the development and maintenance
of nociceptive behaviors in rats. Compared with the ve-
hicle group, i.t. Ad-GFP did not significantly affect PWL
(Figure 5A), PWT (Figure 5B), acetone response score
(Figure 5C), and weight-bearing deficits (Figure 5D) for
the ipsilateral hindpaw of CCI rats. Compared with i.t.
Ad-GFP group, i.t. Ad-PTEN significantly attenuated
CCI-induced thermal hyperalgesia (Figure 5A), mechan-
ical allodynia (Figure 5B), cold allodynia (Figure 5C),
and weight-bearing deficits (Figure 5D) up to 14 days
post injury. In contrast, similar to previous studies
[49,50], the contralateral hindpaw in CCI rats did not
show pain-related behavior (Figure 6). Compared with
i.t. vehicle group, neither i.t. Ad-GFP nor Ad-PTEN sig-
nificantly affected PWL (Figure 6A), PWT (Figure 6B),
or acetone response scores (Figure 6C) for the contralat-
eral hindpaw of CCI rats. In addition, i.t. Ad-GFP- andAd-PTEN-treated CCI rats failed to show obvious ab-
normal behaviors (including locomotor function), and
the naïve-plus-i.t. Ad-PTEN rats exhibited normal loco-
motor function. We then focused on 14 days post injury
to determine whether the modulation of spinal neuroin-
flammatory processes is involved in the maintenance of
the antinociceptive effects of the upregulation of spinal
PTEN by i.t. Ad-PTEN.
The effect of Ad-PTEN on spinal neuroinflammation in
neuropathic rats
For spinal immunohistofluorescence assay, we collected
spinal tissue on day 14 post injury from the following
three groups of rats: (1) sham-operated plus i.t. vehicle,
(2) CCI plus i.t. Ad-GFP, and (3) CCI plus i.t. Ad-PTEN.
OX-42-, GFAP-, and TNF-α-immunoreactive cells were
scattered throughout the ipsilateral dorsal horn of the
lumbar spinal gray matter of sham-operated plus i.t. ve-
hicle (Figure 7A,D,G), CCI plus i.t. Ad-GFP (Figure 7B,
E,H), and CCI plus i.t. Ad-PTEN (Figure 7C,F,I) groups.
Similarly, and as previously reported,[19,22] the immu-
noreactivity of OX-42 (Figure 7B), GFAP (Figure 7E),
and TNF-α (Figure 7H) of CCI plus i.t. Ad-GFP group
were upregulated on day 14 post injury when compared
with the sham-operated plus i.t. vehicle group. CCI-induced
upregulation of OX-42 (Figure 7C), GFAP (Figure 7F),
and TNF-α (Figure 7I) were inhibited by i.t. Ad-PTEN.
Quantification of OX-42 (Figure 7J), GFAP (Figure 7K),
and TNF-α (Figure 7L) immunoreactivity supported the
finding that inhibition of CCI-induced upregulation of
OX-42 and GFAP, which are microglial and astrocytic
immunohistochemical activation markers, as well as
TNF-α, are consistent with the anti-nociceptive effects
of i.t. Ad-PTEN.
Figure 4 The effects of i.t. injection of Ad-PTEN on PTEN in the dorsal lumbar spinal cord. Fourteen days after i.t.; spinal cord sections
(10 μm) are from i.t. injection of vehicle (A), Ad-GFP (B), and Ad-PTEN (C) groups. Immunostaining images of the spinal cord show cells labeled
with PTEN (red). Quantification of PTEN (D) immunoreactivity in the ipsilateral dorsal horn of the lumbar spinal gray matter compared with vehicle
group. Injection (i.t.) of Ad-PTEN significantly upregulated spinal PTEN immunoreactivity. Each bar in (D) represents the mean ± SEM with six
rats per group. Ad-GFP, adenovirus-mediated green fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin homolog
deleted from chromosome 10. Confocal double-immunofluorescent staining of PTEN (red) with NeuN (neuronal-specific marker; (E), green),
GFAP (astrocyte specific marker; (F), green), and OX-42 (microglial specific marker; (G), green) in the dorsal horn region of the lumbar spinal
cord of the i.t. Ad-PTEN group. The merged images of (E), (F), and (G) (yellow; white arrow) indicate co-localization of PTEN with NeuN, GFAP,
and OX-42 immunoreactive cells in the spinal cord, respectively. The confocal results show that spinal PTEN was primarily co-localized with
astrocytes in i.t. Ad-PTEN group. Scale bars are 200 μm for panels A-C and 50 μm for panels E-G. *P < 0.05 compared with the vehicle group.
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signaling in CCI rats
We further examined the effects of i.t. Ad-PTEN on
CCI-induced changes in the spinal PTEN pathway. Wefurther used Western blot analysis to measure changes
in PTEN and phospho-mTOR in the dorsal horn of the
lumbar spinal cord from the following six groups of rats:
(1) sham-operated plus i.t. vehicle 7 days post injury, (2)
Figure 5 The time course of i.t. Ad-PTEN effects on nociceptive behaviors in CCI rats. Ad-PTEN (i.t) prevented CCI-induced development of
pain behaviors with the ipsilateral hindpaw in neuropathic rats up to 14 days post injury, including thermal hyperalgesia (A), mechanical allodynia
(B), cold allodynia (C), and weight-bearing deficits (D). Each point represents the mean ± SEM with six rats per group. *P < 0.05 compared with
CCI plus i.t. vehicle group. Ad-GFP, adenovirus-mediated green fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin
homolog deleted from chromosome 10; CCI, chronic constriction injury; i.t., intrathecal.
Figure 6 The effects of i.t. Ad-PTEN on nociceptive behaviors with the contralateral hindpaw in CCI rats. I.t. Ad-PTEN did not significantly
affect the responses to thermal hyperalgesia (A), mechanical allodynia (B), or cold allodynia (C) tests. Each point represents the mean ± SEM with
six rats per group. Ad-GFP, adenovirus-mediated green fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin homolog
deleted from chromosome 10; CCI, chronic constriction injury; i.t., intrathecal.
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Figure 7 The effects of i.t. Ad-PTEN on CCI-induced microglial and astrocytic activation and upregulation of TNF-α. Spinal cord sections
(10 μm) obtained 14 days post-surgery from sham-operated plus i.t. vehicle (A, D, G), CCI plus i.t. Ad-GFP (B, E, H), and CCI plus i.t. Ad-PTEN (C,
F, I) groups. Immunostaining images show cells labeledwith OX-42 (red; (A-C)) and GFAP (red; (D-F)), TNF-α (red; (G-I)) in the spinal cord. Quantification of
OX-42 (J) and GFAP (K), and TNF-α (L) immunoreactivity in the ipsilateral dorsal horn of the lumbar spinal graymatter. Ad-GFP, adenovirus-mediated green
fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin homolog deleted from chromosome 10; CCI, chronic constriction injury; GFAP,
glial fibrillary acidic protein; TNF, tumor necrosis factor. Each bar in (J-L) represents themean ± SEMwith six rats per group. Ad-PTEN (i.t.) significantly inhibited
CCI-induced upregulation of spinal OX-42, GFAP, and TNF-α immunoreactivity. Scale bars: 200 μm for all images (A-I). *P< 0.05 comparedwith sham-operated
plus i.t. vehicle group; #P< 0.05 comparedwith CCI plus i.t. Ad-GFP.
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Ad-PTEN 7 days post injury, (4) sham-operated plus i.t.
vehicle 14 days post injury, (5) CCI plus i.t. Ad-GFP
14 days post injury, and (6) CCI plus i.t. Ad-PTEN
14 days post injury. The Western blot analysis revealed
both a downregulation of PTEN (Figure 8B) and an up-
regulation of phospho-mTOR (Figure 8C) in the spinal
cord on days 7 and 14 after CCI surgery, which were
both attenuated by i.t. Ad-PTEN. Compared with the
sham-operated plus i.t. vehicle group (Figure 9A), PTEN
immunoreactivity in the CCI plus i.t. Ad-GFP group
(Figure 9B) decreased 14 days post injury. Compared with
the i.t. Ad-GFP group, i.t. Ad-PTEN (Figure 9C) attenu-
ated CCI-induced downregulation of PTEN 14 days post
injury. Compared with the sham-operated plus i.t. vehicle
group (Figure 9D), phospho-mTOR immunoreactivity inthe CCI plus i.t. Ad-GFP group (Figure 9E) increased
14 days post injury. Compared with i.t. Ad-GFP group, i.t.
Ad-PTEN (Figure 9F) attenuated CCI-induced upregula-
tion of phospho-mTOR 14 days post injury. Quantifica-
tion of the immunoreactivity results further confirmed
that i.t. Ad-PTEN significantly attenuated CCI-induced
downregulation of PTEN (Figure 9G) and upregulation
of phospho-mTOR (Figure 9H) 14 days post injury. To
examine the inhibitory effects of i.t. injection of Ad-
PTEN on CCI-induced upregulation of TNF-α and
phospho-mTOR in spinal astrocytes, we prepared tissue
14 days post-surgery from sham-operated plus i.t. vehicle
(Figure 10A,D), CCI plus i.t. Ad-GFP (Figure 10B,E), and
CCI plus i.t. Ad-PTEN (Figure 10C,F) rats to perform
double-immunofluorescent staining. The confocal double-
immunostaining results showed that spinal TNF-α (red;
Figure 8 Effects of the time course of i.t. Ad-PTEN on the spinal PTEN and phospho-mTOR levels in CCI rats. (A) Western blots for PTEN,
phospho-mTOR, and β-actin proteins from sham-operated plus i.t. vehicle 7 days post injury, CCI plus i.t. Ad-GFP 7 days post injury, CCI plus i.t.
Ad-PTEN 7 days post injury, sham-operated plus i.t. vehicle 14 days post injury, CCI plus i.t. Ad-GFP 14 days post injury, and CCI plus i.t. Ad-PTEN
14 days post injury. (B) Relative density of the immunoblot of PTEN. (C) Relative density of the immunoblot of phospho-mTOR. Relative band
intensities of PTEN and phospho-mTOR were quantified by densitometry and indicated as the percent change relative to that for the sham-operated
7 days post injury group (100%). Western blotting revealed that PTEN and phospho-mTOR protein expression were detectable in the sham-operated
group, but CCI-induced downregulation of PTEN and upregulation of phospho-mTOR protein on day 7 and day 14 after CCI surgery were both
attenuated by i.t. Ad-PTEN. Western blotting of β-actin was performed to verify that equivalent amounts of protein were loaded in each lane.
Each bar in (B) and (C) represents the mean ± SEM with three rats per group. *P < 0.05 compared with sham-operated 7 days post injury group.
#P < 0.05 between CCI plus i.t. Ad-PTEN group compared with the same time points in CCI plus i.t. Ad-GFP group. Ad-GFP, adenovirus-mediated
green fluorescent protein; Ad-PTEN, adenovirus-mediated phosphatase and tensin homolog deleted from chromosome 10; CCI, chronic constriction
injury; p-mTOR, phosphorylated mammalian target of rapamycin.
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primarily co-localized with astrocytes in the CCI group,
and i.t. Ad-PTEN significantly attenuated CCI-induced
upregulation of spinal TNF-α (Figure 10C) and phospho-
mTOR (Figure 10F) immunoreactivity in astrocytes.
Discussion
The role of endogenous PTEN in neuropathic and
normal rats
Previous neuroscience studies have focused on the role
of PTEN in axon regeneration [11,51,52], Alzheimer’s
disease [53], Parkinson’s disease [54], ischemic braininjury [12], and spinal cord injury [52,55-57]. To the best
of our knowledge, the present report is the first to ex-
plore the role of spinal PTEN in pain, especially neuro-
pathic pain. Using a spinal immunohistofluorescence
assay system and Western blot analysis, we found that
CCI could elicit downregulation of ipsilateral dorsal
spinal PTEN in rats (Figures 1 and 2). Phosphorylation
of Ser-380 is known to suppress phosphatase activity of
PTEN [58]. We also demonstrated that upregulation
of phospho-PTEN was associated with downregulation
of PTEN 14 days after CCI surgery (Figures 1 and 2).
Phosphorylation of Ser-2448 mTOR is a biomarker for
Figure 9 The inhibitive effect of i.t. Ad-PTEN on CCI-induced downregulation of PTEN and upregulation of phospho-mTOR. Spinal cord
sections (10 μm) obtained 14 days post-surgery from sham-operated plus i.t. vehicle (A, D), CCI plus i.t. Ad-GFP (B, E), and CCI plus i.t. Ad-PTEN
(C, F) groups. Immunostaining images show cells labeled with PTEN (red) (A-C) and phospho-mTOR (red) (D-F) in the spinal cord. Quantification
of PTEN (G) and phospho-mTOR (H) immunoreactivity in the ipsilateral dorsal horn of the lumbar spinal gray matter, and each bar in (G-H)
represents the mean ± SEM with six rats per group. Ad-PTEN (i.t.) significantly attenuated CCI-induced downregulation of spinal PTEN immunoreactivity
and upregulation of spinal phospho-mTOR immunoreactivity. Scale bars: 200 μm for all images (A–F). *P < 0.05 compared with sham-operated plus
i.t. vehicle group; #P < 0.05 compared with CCI plus i.t. Ad-GFP. Ad-GFP, adenovirus-mediated green fluorescent protein; Ad-PTEN, adenovirus-mediated
phosphatase and tensin homolog deleted from chromosome 10; CCI, chronic constriction injury; p-mTOR, phosphorylated mammalian target
of rapamycin.
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hibitory target of PTEN [10-12]. However, there is a lack
of information regarding the changes in spinal phospho-mTOR in CCI rats. Indeed, we found that upregulation
of phospho-mTOR (Figure 1L) was associated with up-
regulation of phospho-PTEN (Figure 1J) after CCI
Figure 10 The effects of i.t. Ad-PTEN on CCI-induced upregulation of TNF-α and phospho-mTOR in spinal astrocytes. Spinal cord
sections (10 μm) obtained 14 days post-surgery from sham-operated plus i.t. vehicle (A, D), CCI plus i.t. Ad-GFP (B, E), and CCI plus i.t. Ad-PTEN
(C, F) groups. Confocal double-immunofluorescent staining of TNF-α (red; A-C) or phospho-mTOR (red; D-F) with GFAP (astrocyte specific
marker; green) in the dorsal horn region of the lumbar spinal cord. The merged images (yellow; white arrow) indicate co-localization of TNF-α
or phospho-mTOR with GFAP immunoreactive cells in the spinal cord. The confocal results showed that spinal TNF-α and phospho-mTOR were
primarily co-localized with astrocytes in the CCI group, whereas i.t. Ad-PTEN significantly attenuated CCI-induced upregulation of spinal TNF-α
and phospho-mTOR immunoreactivity in astrocytes. Scale bars are 50 μm for all images.
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PTEN levels in neuropathic rats, we explored the poten-
tial effects of modulating spinal PTEN pathway on
neuropathic pain. We observed that rats exhibited
mechanical allodynia after i.t. injection of Ad-antisense
PTEN (Figure 3B), which confirms that downregulation
of spinal PTEN is important for nociception, and there-
fore, we suspect that spinal PTEN exerts beneficial ef-
fects against pain.
The analgesic effects of spinal PTEN
Clinical neuropathic pain syndromes are characterized
by evoked pain (hyperalgesia and allodynia) or spontan-
eous pain [60]. We have confirmed these nociceptive
behaviors in the rat CCI model, including thermal
hyperalgesia (Figure 5A), mechanical and cold allodynia
(Figure 5B,C), and weight-bearing deficits (spontaneous
pain; Figure 5D). Ad-PTEN administered i.t. significantly
prevented CCI-induced development of pain behaviorsin neuropathic rats, including thermal hyperalgesia,
mechanical allodynia, and cold allodynia accompanied with
weight-bearing deficits (Figure 5). Central sensitization
within the dorsal horn of the spinal cord could contribute
to the hypersensitive pain behaviors commonly observed
with neuropathic pain [61]. Activation of microglia and
astrocytes could dominate spinal neuroinflammation
[62,63] and accelerate central sensitization as well as the
subsequent development and maintenance of neuro-
pathic pain [20,21]. Upregulation of OX-42 (microglial
marker) and GFAP (astrocytic marker) immunoreactiv-
ity in the spinal dorsal horn are known indicators of
elevated nociceptive states [23-25,64-69], which was fur-
ther confirmed in the CCI rat model by our spinal
immunohistofluorescence data (Figure 7). Many studies
have demonstrated that inhibition of microglial and
astrocytic activation exerts analgesic effects [19,23-25].
Although minocycline, a microglial inhibitor, can pre-
vent neuropathic pain, it cannot reverse established
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spinal microglia in the development phase but not in
the maintenance phase of neuropathic pain [25,70,71].
However, it is still controversial whether spinal micro-
glia contributes to the maintenance of nociception in
neuropathy. As previously reported by Stuesse et al.,
OX-42 activity substantially peaked at around day 7
after nerve injury, and this increase was maintained for
35 days post-injury [68]. Several studies also suggest
that microglial activation is probably important for the
maintenance as well as the early development of neuro-
pathic pain [31,72,73]. A series of studies have shown
that astrocytic activation is implicated in the mainten-
ance of neuropathic pain [64-67,69], indicating the key
role of astrocytes in maintaining neuropathic pain
[74,75]. Activated astrocytes are also reported to be im-
portant contributors of neuropathic pain development
[76]. Our previous studies [19,42,77] and our present find-
ings also indicate that nociceptive behaviors accompany
spinal microglial and astrocytic activation (Figure 7) in
CCI rats. Moreover, our present findings also demonstrate
that the upregulation of spinal PTEN by i.t. Ad-PTEN can
significantly attenuate CCI-induced microglial and astro-
cytic activation in neuropathic rats (Figure 7).
The majority of spinal cells affected by PTEN
The expression and localization of PTEN in pain-related
regions of the central nervous system are not completely
understood. Our confocal double-immunostaining im-
ages of the lumbar spinal dorsal gray matter further
confirmed that astrocytes are a major source of PTEN
expression as compared to neurons and microglia in
sham-operated rats (Figure 2). But certainly, the possibil-
ity that neurons and microglia could also be the source
of PTEN expression cannot be excluded. This finding
supports the hypothesis that the spinal astrocytic
response plays a crucial role in neuropathic pain [19].
Ad-PTEN administered via i.t. injection significantly up-
regulated spinal PTEN immunoreactivity (Figure 4D).
Previous studies have shown that the majority of spinal
cells with adenovirus-mediated target gene overexpres-
sion were astrocytes [78,79]. Similar to the above studies,
the present confocal results showed that spinal PTEN
was primarily co-localized with astrocytes in the i.t. Ad-
PTEN group (Figure 4E,F,G). Moreover, our present
findings also showed that i.t. Ad-PTEN significantly at-
tenuated CCI-induced astrocytic activation in neuro-
pathic rats (Figure 7). This phenomenon was partially
echoed by the finding that PTEN loss resulted in hyper-
trophy and increased proliferation of astrocytes in vivo
[80], which are two characteristics of activated astrocytes
[81]. Based on the above reports and the present results,
we suggest that the prevention of neuropathic pain by
i.t. Ad-PTEN may be mainly associated with its inhibitoryeffects on activated astrocytes, which play key roles in
nociceptive hypersensitization. Previous studies have dem-
onstrated that microglia could interact with astrocytes,
causing downstream biochemical and behavioral responses
to noxious stimuli [82-84]. Additionally, mediators released
by activated microglia induce spinal astrocyte activation,
and blocking these mediators attenuates astrocyte activa-
tion and pain [82-85]. Furthermore, mediators released by
activated astrocytes, in turn, also activate spinal microglia
in neuropathic or focal brain-injured rodents [86,87].
These findings from previous studies suggest that spinal
microglia-astrocyte interactions could promote nocicep-
tive responses (Figure 11A). Therefore, in this study, we
hypothesized that the effect of the upregulation of spinal
PTEN by i.t. Ad-PTEN on attenuating CCI-induced micro-
glial activation may be secondary to the direct inhibition of
activated astrocytes through suppressing the astrocyte-
microglia interaction by reducing the release of astrocytic
mediators (Figure 11B).
Potential analgesic mechanisms of PTEN
Previous studies have found that the activation of spinal
mTOR is required for CCI-induced pain hypersensitivity
[47]. Inhibition of the spinal mTOR pathway by i.t. rapamy-
cin [13] or spinally administered rapamycin ester analogue
CCI-779 [14] attenuates mechanical hyperalgesia in
neuropathic rats. The above studies suggested that the
anti-nociceptive effects produced by inhibition of the
spinal mTOR pathway in neuropathic rats are consistent
with a deleterious role for mTOR in neuropathic rats. In
the present study, we observed upregulation of phospho-
mTOR following CCI surgery (Figure 1L). The findings of
cancer research studies have indicated that PTEN is an
upstream inhibitory mediator of mTOR, which also has
been confirmed in the central nervous system (CNS)
[10-12]. Our results indicated that i.t. Ad-PTEN signifi-
cantly attenuated CCI-induced upregulation of spinal
phospho-mTOR immunoreactivity (Figures 8 and 9). More-
over, similar to the systemic anti-inflammatory effects of
intra-articular Ad-PTEN [17], i.t. Ad-PTEN also has central
anti-inflammatory effects and can inhibit CCI-induced
upregulation of spinal TNF-α (Figure 7). TNF-α, a neuro-
pathic pain-related cytokine [26], caused thermal hyper-
algesia and mechanical allodynia in rats [27]. Moreover,
neuropathic mechanical allodynia in rats was blocked by
i.t. injection of a TNF-soluble receptor, a TNF antagonist
[28]. In the present study, the confocal results from CCI
rats showed that upregulated phospho-mTOR and TNF-α
were localized predominantly to astrocytes, and this
upregulation was inhibited by i.t. Ad-PTEN (Figure 10).
Rapamycin, a specific inhibitor of mTOR, was reported to
inhibit TNF-α release from human vascular smooth
muscle cells in vitro [88]. Other studies have reported that
rapamycin inhibition of mTOR in microglia [89] and
Figure 11 Schematic representation of the possible mechanisms of PTEN involvement in neuropathic pain. (A) Peripheral nerve injury
could downregulate the spinal astrocytic PTEN, which leads to the upregulation of phospho-mTOR and TNF-α and results in neuroinflammation
and nociceptive sensitization. In addition, spinal microglia-astrocyte interactions also promote nociceptive responses. (B) Through the upregulation
of spinal astrocytic PTEN by i.t. Ad-PTEN, peripheral nerve injury-induced upregulation of phospho-mTOR and TNF-α is inhibited, thereby inhibiting
neuroinflammation and nociceptive sensitization. The effect of the upregulation of spinal PTEN by i.t. Ad-PTEN on attenuating peripheral nerve
injury-induced microglial activation may be through suppressing the astrocyte-microglia interaction by reducing the astrocytic mediator TNF-α.
Ad-PTEN, adenovirus-mediated phosphatase and tensin homolog deleted from chromosome 10; p-mTOR, phosphorylated mammalian target of
rapamycin; TNF, tumor necrosis factor.
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suggests that inhibiting mTOR can reduce neuroinflam-
mation [91]. Thus, according to the previous and present
findings, we conclude that one analgesic mechanism of
PTEN may be inhibition of the astrocytic inflammatory
response (upregulated TNF-α) via inhibition of phospho-
mTOR (Figure 11B).
Advantages and future studies of PTEN for neuropathic pain
We suspect that the upregulation of PTEN may be
therapeutic for neuropathic pain, a neuroinflammation-
related disorder. Our present results demonstrate that
PTEN exerts beneficial effects against neuropathic
pain, which highlights three future research directions.
First, it is important and valuable to explore the func-
tions of PTEN through neuroscience research, especiallyneuroinflammation-related disorder mediated by acti-
vated astrocytes. However, a few in vitro [89] and in vivo
[92] studies showed that inhibition of mTOR may
modulate neurons or microglial activation. Therefore,
the possibility that i.t. Ad-PTEN directly affects spinal
neurons or microglia cannot be excluded. Second, Sims
et al. [93] considered the adenovirus to be an efficient
and safe vector for CNS gene delivery, although there
are limitations to adenoviral-mediated PTEN gene ther-
apy. The individuals treated with adenoviral vectors
were previously reported to have experienced systemic
reactions including fever, chill, and hypertension [48].
Although i.t. Ad-PTEN did not significantly affect the
response to thermal hyperalgesia, mechanical allodynia,
or cold allodynia tests on the contralateral hindpaw in
CCI rats (Figure 6). Additionally, i.t. Ad-PTEN-treated
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abnormal external behavior (including locomotor func-
tion). The minimal effective dose and the duration of
PTEN gene therapy still need to be determined in future
research. Third, there is no known PTEN activator for
neuropathic pain, and upregulation of PTEN may serve
as an in vitro index to screen compounds that may be
potential neuropathic pain therapies.Conclusions
This study is a novel step toward understanding the ben-
efits of PTEN on neuropathic pain and provides a foun-
dation for future studies utilizing upregulation of PTEN
in combinational therapies for neuropathic pain.
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